One week after the New York City drug developer Applied Therapeutics announced it was working with regulators and law enforcement to identify and prosecute the anonymous author of a “fraudulent short report,” the company — much more quietly — amended its investor presentation in a way that bolsters accusations made by the author.
According to a Wall Street analyst who spoke with Applied Therapeutics, the addition of new data and clarifying language about a clinical trial to its corporate slide deck on July 9 was done to help investors better understand its work on an experimental drug for a rare metabolic disease.
But the changes to its slide deck were made to information and data that, in their prior form, were red-flagged as inconsistent, sloppy, and misleading by the author of the negative report — raising questions about the company’s true intent.
About the Author Reprints
